Novo Nordisk Chief Executive Officer Mike Doustdar says the profitability of its popular Wegovy weight-loss pill is "decent" and will continue to improve. "If that was not the case, we would not be launching the product in more and more markets," he...
Novo Nordisk Chief Executive Officer Mike Doustdar says the profitability of its popular Wegovy weight-loss pill is "decent" and will continue to improve. "If that was not the case, we would not be launching the product in more and more markets," he tells Bloomberg Television. (Source: Bloomberg)
Lire l’article complet sur le site source
Bloomberg — Markets (EN)